Written by International Journal of Pharmacology and Clinical Sciences, 2024, 13, 3, 75.
Published: November 2024
Type: Drug Review
Authors: Juman Alsaab
Author(s) affiliations:
Juman Alsaab,
Pharm D Ministry of Health, Riyadh, SAUDI ARABIA.
Abstract
OVERVIEW
Regulations: Filsuvez (R) topical gel has been successfully registered for Epidermolysis bullosa treatment in the United States of America (USA), a significant milestone in dermatology.
General Information:
Registered Company: Chiesi Global Rare Diseases.
Regulatory Status: R.X.
Mechanism of Action: unknown regarding treatment of Epidermolysis bullosa. Read More…